<DOC>
	<DOCNO>NCT00004236</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient advanced stomach cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall survival , time disease progression , objective reponse rate , safety profile , quality life patient inoperable gastric adenocarcinoma treat doxorubicin HCl liposome . OUTLINE : Patients receive doxorubicin HCl liposome IV 1 hour every 4 week . Treatment continue 6 course absence unacceptable toxicity disease progression . Patients respond disease may continue therapy past 6 course document disease progression . Quality life assess prior every treatment course . All patient follow 1 month . Patients stable respond disease follow every 3 month death . PROJECTED ACCRUAL : A total 30 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced gastric adenocarcinoma , include adenocarcinoma esophagogastric junction Evaluable disease No CNS involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin normal AST ALT less 3 time upper limit normal ( ULN ) ( 5 time ULN document liver metastasis ) Renal : Creatinine le 1.5 time ULN Cardiovascular : LVEF normal No history New York Heart Association class IIIV heart disease congestive heart failure No unstable cardiovascular disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior primary cancer within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix No hypersensitivity anthracycline therapy No history severe hypersensitivity reaction product contain Chremophor EL ( e.g. , cyclosporine teniposide injection concentrate ) No significant medical disorder ( e.g. , active uncontrolled infection ) would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy le 1/3 hematopoietic site recover Surgery : Not specify Other : At least 30 day since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>